콘텐츠로 건너뛰기
Merck
모든 사진(2)

주요 문서

SML3942

Sigma-Aldrich

DUB-IN-2

≥98% (HPLC)

동의어(들):

9-Ethoxyimino-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, DUB Inhibitor 2, DUBs Inhibitor 2, DUBs-IN-2, Deubiquitinase Inhibitor 2

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C15H9N5O
CAS Number:
Molecular Weight:
275.26
UNSPSC 코드:
12352200
NACRES:
NA.77

Quality Level

분석

≥98% (HPLC)

양식

powder

색상

white to beige

solubility

DMSO: 2 mg/mL, clear

저장 온도

-10 to -25°C

생화학적/생리학적 작용

Potent and selective ubiquitin specific peptidase USP8 deubiquitinase (DUB) inhibitor.

DUBs-IN-2 is a potent and selective ubiquitin specific peptidase USP8 deubiquitinase (DUB) inhibitor (IC50 = 280 nM/USP8, >100 µM/USP7). DUBs-IN-2 inhibits the proliferation of gastric cancer (GC) cell NCI-N87 in cultures (IC50 = 480 nM post 3-day incubation) and NCI-N87-derived tumor growth in mice in vivo (2 mg/kg/d 5x per wk) by promoting HER-2 degradation.

픽토그램

Exclamation mark

신호어

Warning

유해 및 위험 성명서

예방조치 성명서

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Jiangang Sun et al.
OncoTargets and therapy, 13, 9941-9952 (2020-10-30)
Referring to global cancer statistics, the incidence of gastric cancer (GC) was ranked sixth; however, detailed mechanisms underlying its development were not thoroughly investigated. Previous studies have reported that inhibition of ubiquitin-specific peptidase 8 (USP8) induced degradation of several receptor
Matteo Colombo et al.
ChemMedChem, 5(4), 552-558 (2010-02-27)
High-throughput screening highlighted 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile (1) as an active inhibitor of ubiquitin-specific proteases (USPs), a family of hydrolytic enzymes involved in the removal of ubiquitin from protein substrates. The chemical behavior of compound 1 was examined. Moreover, the synthesis and in
Wenjun Xiong et al.
Nature communications, 13(1), 1700-1700 (2022-04-02)
Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15-25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.